Topic Archives: Astellas Pharma (YPH.F ALPMY ALPMF)

In his tearjerker “Sisters of Mercy,” Leonard Cohen sings, I’ve been where you’re hanging and think I can see how you’re pinned. Although I am less inclined to bash the FDA than many, it has recently let modern medical practice place many patients in an undesirable situation. What if there was a very powerful drug, […]

Comments

  • Avatar

    Astellas Pharma is a big Japanese company - 17,000 employees...

  • Avatar

    http://www.mitobridge.com/news/publications It seems like Mitobridge out of Cambridge MA. is also looking at Mitochondri...

  • Avatar

    $KITE: Review article in Los Angeles Times High-flying Kite could score big with new cancer treatment [Los Angeles T...

  • Avatar

    Medivation (MDVN) and Astellas Pharma (ALPMY)just threw out some pretty impressive data in their Phase 2 Strive trial fo...

  • Avatar

    Has anyone looked at Aveo Oncology (AVEO). After a period of disappointing news, management is reporting "significant im...

  • Avatar

    Cubist sounds like the likely candidate. But until they resolve the patent infringement against Teva (possible trial dat...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch